Institution
University of California, Davis
Education•Davis, California, United States•
About: University of California, Davis is a education organization based out in Davis, California, United States. It is known for research contribution in the topics: Population & Gene. The organization has 78770 authors who have published 180033 publications receiving 8064158 citations. The organization is also known as: UC Davis & UCD.
Topics: Population, Gene, Poison control, Context (language use), Medicine
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Vasomotor symptoms were reported most often in all racial/ethnic groups in late perimenopause and nearly as often in postmenopause, and among the risk factors assessed, vasomotor Symptoms were most strongly associated with menopausal status.
Abstract: Objectives. We investigated whether vasomotor symptom reporting or patterns of change in symptom reporting over the perimenopausal transition among women enrolled in a national study differed according to race/ethnicity. We also sought to determine whether racial/ethnic differences were explained by sociodemographic, health, or lifestyle factors.Methods. We followed 3198 women enrolled in the Study of Women’s Health Across the Nation during 1996 through 2002. We analyzed frequency of vasomotor symptom reporting using longitudinal multiple logistic regressions.Results. Rates of vasomotor symptom reporting were highest among African Americans (adjusted odds ratio [OR]=1.63; 95% confidence interval [CI]=1.21, 2.20). The transition to late perimenopause exhibited the strongest association with vasomotor symptoms (adjusted OR = 6.64; 95% CI = 4.80, 9.20). Other risk factors were age (adjusted OR=1.17; 95% CI=1.13, 1.21), having less than a college education (adjusted OR = 1.91; 95% CI = 1.40, 2.61), increasing...
710 citations
••
TL;DR: This review will focus on the current understanding of MuRF1 and MAFbx in skeletal muscle, highlighting the critical questions that remain to be answered.
Abstract: Muscle RING finger 1 (MuRF1) and muscle atrophy F-box (MAFbx)/atrogin-1 were identified more than 10 years ago as two muscle-specific E3 ubiquitin ligases that are increased transcriptionally in skeletal muscle under atrophy-inducing conditions, making them excellent markers of muscle atrophy. In the past 10 years much has been published about MuRF1 and MAFbx with respect to their mRNA expression patterns under atrophy-inducing conditions, their transcriptional regulation, and their putative substrates. However, much remains to be learned about the physiological role of both genes in the regulation of mass and other cellular functions in striated muscle. Although both MuRF1 and MAFbx are enriched in skeletal, cardiac, and smooth muscle, this review will focus on the current understanding of MuRF1 and MAFbx in skeletal muscle, highlighting the critical questions that remain to be answered.
709 citations
••
University of Paris-Sud1, Tel Aviv University2, University of California, Irvine3, French Institute of Health and Medical Research4, National Institutes of Health5, University of Glasgow6, University of California, Davis7, University of Copenhagen8, University of Milan9, Harvard University10, University of Tokyo11, Kumamoto University12, Merck KGaA13, University of Birmingham14, University of Brescia15, Kindai University16
TL;DR: This work reviews this extended family of chemokine receptors and Chemokine-binding proteins at the basic, translational, and clinical levels, including an update on drug development and introduces a new nomenclature for atypical chemokin receptors with the stem ACKR (atypicalChemokine receptor).
Abstract: Sixteen years ago, the Nomenclature Committee of the International Union of Pharmacology approved a system for naming human seven-transmembrane (7TM) G protein-coupled chemokine receptors, the large family of leukocyte chemoattractant receptors that regulates immune system development and function, in large part by mediating leukocyte trafficking. This was announced in Pharmacological Reviews in a major overview of the first decade of research in this field [Murphy PM, Baggiolini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, and Power CA (2000) Pharmacol Rev 52:145–176]. Since then, several new receptors have been discovered, and major advances have been made for the others in many areas, including structural biology, signal transduction mechanisms, biology, and pharmacology. New and diverse roles have been identified in infection, immunity, inflammation, development, cancer, and other areas. The first two drugs acting at chemokine receptors have been approved by the U.S. Food and Drug Administration (FDA), maraviroc targeting CCR5 in human immunodeficiency virus (HIV)/AIDS, and plerixafor targeting CXCR4 for stem cell mobilization for transplantation in cancer, and other candidates are now undergoing pivotal clinical trials for diverse disease indications. In addition, a subfamily of atypical chemokine receptors has emerged that may signal through arrestins instead of G proteins to act as chemokine scavengers, and many microbial and invertebrate G protein-coupled chemokine receptors and soluble chemokine-binding proteins have been described. Here, we review this extended family of chemokine receptors and chemokine-binding proteins at the basic, translational, and clinical levels, including an update on drug development. We also introduce a new nomenclature for atypical chemokine receptors with the stem ACKR (atypical chemokine receptor) approved by the Nomenclature Committee of the International Union of Pharmacology and the Human Genome Nomenclature Committee.
709 citations
••
29 May 1995TL;DR: This paper provides the first treatment of session key distribution in the three-party setting of Needham and Schroeder in the complexity-theoretic framework of modern cryptography, assuming the (minimal) assumption of a pseudorandom function.
Abstract: We study session key distribution in the three-party setting of Needham and Schroeder. (This is the trust model assumed by the popular Kerberos authentication system.) Such protocols are basic building blocks for contemporary distributed systems—yet the underlying problem has, up until now, lacked a definition or provably-good solution. One consequence is that incorrect protocols have proliferated. This paper provides the first treatment of this problem in the complexitytheoretic framework of modern cryptography. We present a definition, protocol, and a proof that the protocol satisfies the definition, assuming the (minimal) assumption of a pseudorandom function. When this assumption is appropriately instantiated, our protocols are simple and efficient. Abstract appearing in Proceedings of the 27th ACM Symposium on the Theory of Computing, May 1995.
709 citations
••
TL;DR: In this article, the authors evaluate the feasibility of providing all energy for all purposes (electric power, transportation, and heating/cooling), everywhere in the world, from wind, water, and the sun (WWS).
708 citations
Authors
Showing all 79538 results
Name | H-index | Papers | Citations |
---|---|---|---|
Eric S. Lander | 301 | 826 | 525976 |
Ronald C. Kessler | 274 | 1332 | 328983 |
George M. Whitesides | 240 | 1739 | 269833 |
Ronald M. Evans | 199 | 708 | 166722 |
Virginia M.-Y. Lee | 194 | 993 | 148820 |
Scott M. Grundy | 187 | 841 | 231821 |
Julie E. Buring | 186 | 950 | 132967 |
Patrick O. Brown | 183 | 755 | 200985 |
Anil K. Jain | 183 | 1016 | 192151 |
John C. Morris | 183 | 1441 | 168413 |
Douglas R. Green | 182 | 661 | 145944 |
John R. Yates | 177 | 1036 | 129029 |
Barry Halliwell | 173 | 662 | 159518 |
Roderick T. Bronson | 169 | 679 | 107702 |
Hongfang Liu | 166 | 2356 | 156290 |